

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):



- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 89102441.6

(20) Int. Cl.<sup>4</sup>: C 12 N 15/00  
C 12 N 1/20, A 01 H 1/00

(22) Date of filing: 22.12.83

(30) Priority: 13.01.83 EP 83100258

(43) Date of publication of application:  
14.06.89 Bulletin 89/24

(24) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(60) Publication number of the earlier application in  
accordance with Art. 78 EPC: 0 116 718

(71) Applicant: Max-Planck-Gesellschaft zur Förderung der  
Wissenschaften e.V.  
Bunsenstrasse 10  
D-3400 Göttingen (DE)

(72) Inventor: Zambryski, Patricia  
Holdaal 46  
B-9000 Gent (BE)

Schell, Josef S.  
Max-Planck-Institut Vogelsang  
D-5000 Köln 30 (DE)

Hemaisteens, Jean Pierre E.C.  
158 Rens Desmedtstraat  
B-1150 Brussels (BE)

van Montagu, Marc Charles  
De Stassart Straet 120  
B-1050 Brussels (BE)

Herrera Estrella, Luis Rafael  
Holdaal 46  
B-9000 Gent (BE)

Leemans, Jan Josef August  
Putsesteenweg 252  
B-2920 Bonheiden (BE)

(74) Representative: Vossius & Partner  
Siebertstrasse 4 P.O. Box 88 07 67  
D-8000 München 86 (DE)

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): DSM 2792, 2793, 2796, 2797, 2798, 2799, 2833.

(84) Non-oncogenic Ti plasmid vector system and recombinant DNA molecules for the introduction of expressible genes into plant cell genomes.

(57) Described is a non-oncogenic Ti plasmid vector system and recombinant DNA molecules for the introduction of expressible genes into plant cell genomes. Furthermore, corresponding transformed *Agrobacterium* strains and processes for the production of plant cells and plants containing foreign DNA sequences are described. (Fig. 10)




Fig. 1

EP 0 320 500 A2

## Description

**NON-ONCOGENIC TI PLASMID VECTOR SYSTEM AND RECOMBINANT DNA MOLECULES FOR THE INTRODUCTION OF EXPRESSIBLE GENES INTO PLANT CELL GENOMES**

## Technical field of invention

The invention relates to a non-oncogenic TI plasmid vector system and recombinant DNA molecules for the introduction of expressible genes into plant cell genomes. Furthermore, the invention relates to the corresponding transformed *Agrobacterium* strains and to processes for the production of plant cells and plants containing foreign DNA sequences.

The expressible genes contained in the non-oncogenic TI plasmid vector system and the recombinant DNA molecules of the present invention code for products, e.g. amino acids or polypeptides, useful for the growth of the plant or for improving its quality as nutrient, or for the production of valuable metabolites (e.g. alkaloids or steroid precursors).

In the description the following terms are used :  
hom site : region of DNA where mob functions specifically interact and initiate autonomous DNA transfer.

Border sequence : DNA sequence which contains the ends of the T-DNA

Broad-host-range replicon : a DNA molecule capable of being transferred and maintained in many different host cells.

Callus tissue : a mass of unorganized and undifferentiated cells.

Cloning : the process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction.

or better:

the process of isolating a particular organism or part thereof, and the propagation of this subtraction as a homogenous population.

Cloning vehicle : a plasmid, phage DNA or other DNA sequences which are able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance, or ampicillin resistance. A cloning vehicle is often called vector.

Coding sequence : DNA sequence which determines the amino acid sequence of a polypeptide.

Cointegrate : the structure resulting from a single cross-over event between two circular DNA molecules.

Complementation in trans : process whereby a DNA molecule (replicon) which is not physically linked to another replicon can provide a diffusible substance which is missing and required by the other nonlinked replicon.

Conjugation : the process whereby DNA is transferred from bacteria of one type to another type

during cell-to-cell contact.

Crossing-over : the process of exchange of genetic material between homologous DNA sequences.

Deletion substitution : removal of one DNA sequence and its replacement by a different DNA sequence.

Differentiation : the process whereby descendants of a cell achieve and maintain specialization of structure and function.

DNA sequence or DNA segment : a linear array of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

Double cross-over : the process of resolution of a cointegrate structure into two circular DNA molecules. This process is used to exchange genetic information. One of the DNA circles has two regions of homology with the target DNA through which recombination can occur; these two regions bracket a nonhomologous DNA sequence which is to be exchanged with the target DNA. If this second cross-over occurs in the same region of DNA as the first, the original DNA circles will be generated. If this second cross-over occurs in the second homologous region, genetic exchange will be occurred between the two circles.

Expression : the process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation.

Expression control sequence : a sequence of nucleotides that controls and regulates expression of structural genes when operatively linked to those genes.

F-type plasmid : plasmid carrying the F (fertility) factor which allows the transfer of a copy of the plasmid to a host not carrying the F-factor.

Gene : a DNA sequence composed of two parts, (1) the coding sequence for the gene product, and (2) the sequences in the promoter region which control whether or not the gene will be expressed.

Genome : the entire DNA of a cell or a virus. It includes inter alia the structural genes coding for the polypeptide(s), as well as operator, promoter and ribosome binding and interaction sequences, including sequences such as the Shine-Dalgarno sequences.

Genotype : the sum total of the genetic information contained in an organism.

Homologous recombination : recombination between two regions of DNA which contain homologous sequences.

I-type plasmid : a group of autotransferable plasmids of a different incompatibility group than F.

Incompatibility : when two DNA molecules are not capable of coexisting in the same cell in the absence of selective pressure.

Insertion : addition of a DNA sequence within the DNA sequence of another molecule.

Leader sequence : the region of an mRNA molecule extending from the 5' end to the beginning of the

first structural gene; it also includes sites important to initiate translation of the coding sequence of the structural gene.

**Meiosis** : two successive divisions that reduce the starting number of 4 n chromosomes to 1 n in each of four product cells. This process is important in sexual reproduction.

**mob (mobilization functions)** : a set of products which promote DNA transfer only in combination with tra functions. Mob can promote transfer of plasmids containing a bom site.

**Mobilization** : the process whereby one DNA molecule which is not able to transfer to another cell is helped to transfer by another DNA molecule.

**Mobilization helper plasmid** : a plasmid capable of providing diffusible products which another plasmid lacks for transfer to another host cell.

**Nonconjugative recombinant plasmid** : a DNA molecule which is not capable of being transferred by itself from its host cell to another host cell during cell-to-cell contact. For transfer it will need further functions supplied by other DNA, e.g. by (a) helper plasmid(s).

**Nucleotide** : a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via a glycosidic bond (1' carbon of the pentose) and that combination of base and sugar is a nucleoside. The base characterizes the nucleotide. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C"), and thymine ("T"). The four RNA bases are A, G, C, and uracil ("U").

**Phenotype** : the observable characteristics of an individual resulting from the interaction between the genotype and the environment in which development occurs.

**Plasmid** : a nonchromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism are changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (Tc<sup>R</sup>) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called "transformant".

**Polypeptide** : a linear series of amino acids connected one to the other by peptide bonds between the  $\alpha$ -amino and carboxy groups of adjacent amino acids.

**Promoter region** : DNA sequences upstream to the start of the coding sequence which regulate transcription of the gene.

**Promoter sequence** : sequence at which RNA polymerase binds and promotes the faithful transcription of downstream sequences.

**Recombinant DNA molecule or hybrid DNA** : a hybrid DNA sequence comprising at least two nucleotide sequences, the first sequence not normally being found together in nature with the second.

**Recombination** : the creation of a new association of DNA molecules or parts of DNA molecules.

**Region of homology** : a region of DNA which shares

the same nucleotide sequence as that found in a region of another DNA.

**Replicon** : a self-replicating genetic element possessing a site for the initiation of DNA replication and genes specifying the necessary functions for controlling replication.

**Restriction fragment** : a DNA molecule resulting from double-stranded cleavage by an enzyme which recognizes a specific target DNA sequence.

**RNA polymerase** : enzyme which results in the transcription of DNA into RNA.

**Selectable marker gene** : a DNA sequence which, when expressed, gives that cell a growth advantage over cells which do not contain that DNA sequence, when all cells are in a growth medium which can distinguish the two types of cells. Commonly used selectable marker genes are those which encode resistance to antibiotics.

**Single cross-over** : the process of recombining two circular DNA molecules to form a cointegrate larger circle.

**Structural gene** : a gene which codes for a polypeptide.

**T-DNA** : portion of the Ti plasmid as it is found stably integrated into the plant cell genome.

**T-region** : portion of the Ti plasmid which contains the DNA sequences which are transferred to the plant cell genome.

**Ti plasmid** : large plasmids found in strains of *Agrobacterium tumefaciens* containing the genetic information for tumor (crown gall) induction on susceptible plants.

**TL-DNA and TR-DNA** : octopine crown gall tumor cells can contain two T-DNA sequences, a left T-DNA, i.e. TL-DNA, and a right TR-DNA. TL-DNA contains sequences also found in common with T-DNA of nopaline tumor cells whereas TR-DNA does not.

**tra (transfer functions)** : both plasmid-encoded diffusible products and sites of action utilized during DNA transfer between cells, e.g. products required to make a bridge between two cells and the site at which DNA transfer is initiated.

**Transcription** : the process of producing mRNA from a structural gene

or: the process involving base pairing whereby the genetic information contained in DNA is used to order a complementary sequence of bases in an RNA chain.

**Transformation** : genetic modification induced by the incorporation of exogenous DNA into the DNA complement of a cell.

**Translation** : the process of producing a polypeptide from mRNA or : the process whereby the genetic information present in an mRNA molecule directs the order of specific amino acids during the synthesis of a polypeptide.

**Undifferentiated phenotype** : a homologous appearance of cells in a tissue without any specialized parts.

**Vector** : a DNA molecule designed for transfer between different host cells.

# Background Art

The development of recombinant DNA techniques has made the genetic engineering of microorganisms a challenging prospect. These techniques might be extended to multicellular eukaryotes, if complete organisms could be regenerated from single somatic cells. The cells of some higher plants exhibit excellent regeneration capacities and, therefore, are good materials for the genetic engineering of high organisms.

A major problem for the genetic engineering of plants is the availability of a system for the introduction of exogenous (foreign) DNA into the plant genome. Such a system is provided by the tumor-inducing (Ti) plasmids carried by the Gram-negative soil bacterium *Agrobacterium tumefaciens*. This organism has been shown to cause a neo-plastic transformation, called "crown gall", of wounded tissue of a very wide range of dicotyledonous plants. The proliferating neo-plasms synthesize novel, Ti-specified metabolites, called opines. The molecular basis of this transformation is the transfer and stable integration of a well-defined T-DNA (transferred DNA) fragment of the Ti plasmid in the plant cell genome. In other words, crown gall tumors contain in their chromosomal DNA a DNA segment called the T-DNA which is homologous to DNA sequences in the Ti plasmid used to induce the tumor line. In all cases, this T-DNA corresponds to, and is colinear with, a continuous stretch of Ti plasmid DNA which is, therefore, called the T-region.

Ti plasmids are classified according to the type of opine synthesized in crown gall cells. *Agrobacterium* strains which induce the synthesis of nopaline [N- $\alpha$ -(1,3-dicarboxypropyl)-L-arginine] in crown gall cells are called nopaline strains, and strains which induce the synthesis of octopine [N- $\alpha$ -(N-1-carboxyethyl)-L-arginine] are called octopine strains. These are the most commonly used *Agrobacterium* strains.

The use of T-DNA as a vector for plant genetic engineering was demonstrated in a model experiment in which the 14 kb bacterial transposon Tn7 was inserted *in vivo* near the right border of the T-DNA from the Ti plasmid of the strain *Agrobacterium* T37. Nopaline synthesis was eliminated in the tumors incited by *agrobacteria* carrying this Ti plasmid. Furthermore, Southern blotting hybridizations revealed that the entire Tn7 was present in the chromosomal DNA of these tumors as part of an otherwise normal T-DNA sequence (Hernalsteens *et al.*, *Nature* 287 (1980), 654-656; Holsters *et al.*, *Mol. Gen. Genet.* 185 (1982), 283-289). Thus, the introduction of this 14 kb DNA fragment into the 23 kb T-DNA has not altered the latter's ability to be transferred to the plant cell genome.

The borders of the T-DNA from the Ti plasmid of the nopaline strain *Agrobacterium* T37 have been very precisely determined. It is only a portion, roughly 23 kb, of the entire nopaline Ti plasmid. Furthermore, the borders of the T-DNA are known; the nucleotide sequences which define the borders of the T-DNA have been determined and compared with the same region of the nopaline Ti plasmid (Zambryski *et al.*, *Science* 209 (1980), 1385-1391; Zambryski *et al.*, *J. Mol. Appl. Genet.* 1 (1982),

361-370). The borders of the T-region are most probably involved in the integration of the T-DNA into the plant cell genome.

Knowledge of the T-DNA sequences which define the borders of the transferred DNA is a basic requirement for the use of the Ti plasmid as a vector for DNA transfer to plant cells. Thus, foreign DNA can be inserted within these borders to ensure its transfer to the plant cell genome. In addition, if one expects to utilize this system it is important that the transformed plant cells are normal rather than tumorous in their growth properties. To produce normal cells after T-DNA transfer requires knowledge of the functions encoded by the T-DNA itself. Thus, the T-region of the Ti plasmid has been subjected to intense genetic analysis to determine which regions are responsible for the tumor phenotype.

The T-DNA encodes functions which are responsible for the crown gall phenotype. The genes have been localized to specific regions of the T-DNA (Leemans *et al.*, *EMBO J.* 1 (1982), 147-152; Willmitzer *et al.*, *EMBO J.* 1 (1982), 139-146). In general, there are at least 4 genes which control the undifferentiated phenotype of tumor callus tissue. Mutants in these genes can either lead to transformed tissues which appear shoot-like or root-like. The latter results are especially important if one hopes to transfer DNA to plants for expression in normal plant tissue rather than tumor tissue.

Recently, a mutant Ti plasmid was found to induce transformed shoots which were capable for regenerating into completely normal plants. These plants were fertile and even transmitted T-DNA specific sequences through meiosis, i.e. progeny plants still contained T-DNA-specific sequences (Otten *et al.*, *Mol. Gen. Genet.* 183 (1981), 209-213). However, the transformed plant tissue contained in its chromosomal DNA a T-DNA which was very much reduced in size due to the generation of a large deletion which removed the region of the T-DNA controlling the tumor phenotype. It is not known whether the deletion occurred during the initial transformation event or as a subsequent event leading to shoot formation.

The Ti plasmids are large (200 kb) and many genes located at different sites on the Ti plasmid are involved in the transformation of plant cells. Therefore, it is not possible to construct a small Ti plasmid-derived cloning vector with unique endonuclease recognition sites at appropriate locations within the T-region, and possessing all functions essential for T-DNA transfer and stable incorporation into the plant cell genome. One known way to introduce a chosen DNA fragment into specific restriction enzyme cleavage sites of the T-region of a Ti plasmid has been to construct cloning plasmids which are able to replicate in *Agrobacterium* as well as in *Escherichia coli*, and which contain a chosen restriction fragment of the T-DNA. Such cloning plasmids were denoted "intermediate vectors". Such intermediate vectors were used to analyze the functions encoded by the T-region (Leemans *et al.*, *J. Mol. Appl. Genet.* 1 (1981), 149-164).

# Disclosure of the invention

The present invention relates to a process for the introduction of expressible genes into plant cell genomes. It is one of the objects of the present invention to provide modified acceptor Ti plasmids which allow the introduction of any gene(s) of interest into these plasmids. The gene(s) of interest to be introduced is (are) contained within a novel intermediate cloning vector carrying a region of homology with a corresponding region in the acceptor Ti plasmid. The intermediate cloning vectors are a further object of this invention.

The introduction of the gene(s) of interest into the acceptor Ti plasmids is achieved by a single cross-over event which occurs within the two homologous DNA segments of the acceptor Ti plasmid harbored in *Agrobacterium* and the intermediate cloning vector. The intermediate cloning vector is mobilized from *Escherichia coli* where it is propagated to *Agrobacterium* using helper plasmids. Such helper plasmids and their functions for mobilization are known (Finnegan et al., *Mol. Gen. Genet.* 185 (1982), 344-351; Figurski et al., *Proc. Natl. Acad. Sci. USA* 76 (1979), Ditta et al., *Proc. Natl. Acad. Sci. USA* 77 (1980), 7347). The result of the single cross-over event in *Agrobacterium* is a hybrid Ti plasmid vector. Such hybrid Ti plasmid vectors are a further object of the invention.

The resulting hybrid plasmid vectors harbored in *Agrobacterium* (hereinafter called vector composition) can be used directly to infect plant cells which are subsequently screened for the expression of the product(s) of the gene(s) of interest. This process for preparing transformed plant cells by infection of plant cells with the vector composition, and the transformed plant cells, as well as plants generated therefrom are further objects of this invention. This strategy is applicable to any of the plant-transferable plasmids of *Agrobacterium*.

## Description of drawings

Fig. 1 illustrates one embodiment of an acceptor Ti plasmid of the invention which is the result of a deletion of the internal portion of the T-region, except for the border sequences (1) and (2). The border sequences are essential for the integration of the T-region into a plant cell genome. The region (3) between border sequences (1) and (2) is the DNA segment which will be transferred to the plant. The acceptor Ti plasmid contains a DNA segment (3) with a DNA sequence which is homologous with at least a part of a DNA sequence in an intermediate cloning vector permitting integration of the intermediate cloning vector via a single cross-over event. The Ti plasmid region (4) codes for functions which are essential for the transfer by *Agrobacterium* of the T-region into plant cell genomes. This region has been designated as vir-region.

Fig. 2 illustrates an intermediate cloning vector of the invention to be inserted by a single cross-over event into the acceptor Ti plasmid of Fig. 1. It contains a cloning vehicle DNA

segment (3') with a DNA sequence which is homologous with at least part of the DNA segment (3) of the acceptor Ti plasmid permitting the desired single cross-over event. Moreover, the intermediate cloning vector contains a gene or group of genes (5) of interest having its natural promoter sequence. In general plant genes can be used in this construction as they are more likely to be expressed. However, in principle any natural gene of interest can be inserted. The intermediate cloning vector may also contain a selectable marker gene (6). This gene should contain a promoter sequence which permits expression of the gene in plant cells. Plant cells containing this marker gene should have a selective growth advantage over cells without this gene; in this way plant cells which have been transformed by DNA containing this marker gene can be distinguished from untransformed plant cells.

Fig. 3 illustrates another embodiment of an intermediate cloning vector of the invention which is similar to the intermediate cloning vector of Fig. 2, and is to be inserted by a single cross-over event into the acceptor Ti plasmid of Fig. 1. It contains the cloning vehicle DNA segment (3'), an exogenous promoter sequence (8) allowing regulated expression of the gene(s) of interest (7), and, if desired, a marker gene (6).

Fig. 4 schematically illustrates the construction of hybrid Ti plasmid vectors of the invention from the acceptor Ti plasmid of Fig. 1, and the intermediate cloning vectors of Figs 2 and 3 by a single cross-over event.

Fig. 5 outlines the steps involved in the genetic transfer of an intermediate cloning vector from *E. coli* to *Agrobacterium* containing an acceptor Ti plasmid. The first step is in the conjugation of the *E. coli* strain (1) containing the intermediate cloning vector to another *E. coli* strain (2) which contains two helper plasmids for the later conjugation to *Agrobacterium*. One helper plasmid contains DNA sequences important for plasmid transfer (*tra*) and the other helper plasmid contains sequences which are important for the mobilization (*mob*). When these helper plasmids are introduced by conjugation into *E. coli* strain (1), the intermediate cloning vector contained therein will be capable of being transferred to other bacterial strains. The *tra* and *mob* helper plasmids also contain antibiotic resistance markers *Ab<sup>ra</sup>* and *Ab<sup>mb</sup>* which are different from those found in the intermediate cloning vector (*Ab<sup>rt</sup>*). Thus, the presence of all the plasmids can be monitored on selective media. A mobilizing strain (3) is obtained. This mobilizing strain (3) is conjugated to an *A. tumefaciens* strain (4) which contains the acceptor Ti plasmid of Fig. 1 followed by selection for antibiotic resistance marker(s) of the intermediate cloning vector. As the intermediate cloning vector cannot replicate in *Agrobacterium*, it can only be maintained if it has formed a colintegrate with the recipient

acceptor Ti plasmid; this colintegrate structure in *Agrobacterium* (5) is the final hybrid Ti plasmid used to transfer DNA into plant cell genomes.

Fig. 6 illustrates the construction of a model acceptor Ti plasmid (A) which is analogous to that shown in Fig. 1. Here, a double cross-over event occurs between a Ti plasmid and another plasmid containing a DNA sequence which is to replace a portion of the original Ti plasmid. More specifically, the smaller plasmid contains the border sequences of the T-region (1; 2) in a cloning vehicle (3). A double cross-over results in the deletion of the internal portion T of the T-region and its replacement by the cloning vehicle. The acceptor Ti plasmid (A) obtained is capable of transferring DNA contained between the border sequences (1; 2) into plant cell genomes. The resulting transformed plant DNA will not produce tumorous crown gall tissue as the genes controlling neoplastic growth are deleted in the Ti plasmid (A). Ti plasmid (A) is a very generalized acceptor Ti plasmid for any intermediate cloning vector with homology with cloning vehicle (3). The cloning vehicle (3) may be a conventional plasmid, such as pBR322 (or its derivatives).

Fig. 7 illustrates schematically the steps leading to the construction of an intermediate cloning vector in *E. coli* host cells. A gene of interest (5) bracketed by restriction endonuclease site R1 and a selectable marker gene (6) bracketed by restriction endonuclease site R2 are inserted into a cloning vehicle (3) containing single restriction sites for the enzymes R1 and R2. All three molecules are digested with restriction enzymes R1 and/or R2 and ligated together using DNA ligase to form the intermediate cloning vector. The cloning vehicle 3' must also contain additional DNA sequences which code for antibiotic resistance (AB<sup>r</sup>) to use as a selectable marker for bacterial genetics. The gene of interest (5) may be under the control of its natural promoter or of an exogenous promoter as outlined in Figs. 2 and 3.

Fig. 8 illustrates the construction of another embodiment of an acceptor Ti plasmid (B) of the invention. Here, a double cross-over event occurs between a Ti plasmid and a cloning vehicle (3) which contains DNA sequences (9) and (10) which are homologous to Ti sequences just outside the border sequences (1) and (2) respectively. The double cross-over event results in the deletion of the entire T-region T including the border sequences (1) and (2) and its replacement with the cloning vehicle (3). Ti plasmid (B) is an acceptor for intermediate cloning vectors which contain the gene of interest cloned between the border sequences (1) and (2); (see Fig. 9).

Fig. 9 illustrates an intermediate cloning vector of the invention to be inserted by a single cross-over event into the acceptor Ti plasmid (B) of Fig. 8. It contains the border sequences (1) and (2) which flank the gene(s) of interest

(5). It also contains a cloning vehicle sequence (3') which is at least partially homologous to the cloning vehicle sequence (3) in the acceptor Ti plasmid (B) to allow homologous recombination between the two plasmids.

Fig. 10 schematically illustrates the construction of hybrid Ti plasmid vectors of the invention from the acceptor Ti plasmid (B) of Fig. 8 and the corresponding intermediate cloning vector of Fig. 9. A single cross-over event introduces the intermediate cloning vector of Fig. 9 into the acceptor Ti plasmid (B) of Fig. 8.

The following figures 11 to 20 more specifically illustrate the invention.

Fig. 11 illustrates the insertion of the 5.2 kb HindIII fragment AcgB into pBR322 (see also Zambryski et al., *Science* 209 (1980), 1385-1391). This fragment AcgB contains the right and left border regions of the nopaline Ti plasmid T-DNA. This clone pAcgB is used in the construction of acceptor plasmid pGV3850, an "A-like" acceptor plasmid as shown in Fig. 6. It is obvious to those skilled in the art that clone analogous to clone pAcgB can be obtained by using the cloned restriction fragments which contain the left and right border region of a wild-type Ti plasmid.

Fig. 12 illustrates the T-region of nopaline Ti plasmid pGV3839. The HindIII restriction endonuclease sites are indicated as (H). Mutated HindIII fragment 19 is indicated (19'). The acetylphosphotransferase gene providing kanamycin or neomycin resistance is indicated as apt and is located in the black box area. The border of the T-region are indicated by arrows. The nopaline synthase gene is indicated by nos. The numbers refer to the sizes of the restriction fragments according to Depicker et al., *Plasmid* 3 (1980), 193-211. The construction of the Ti plasmid pGV3838 can be taken from example 1, and the two references cited.

Fig. 13 illustrates the construction of acceptor Ti plasmid pGV3850. The plasmid pBR322-pAcgB (Fig. 11) is depicted in a linearized form. The pBR322 sequences are indicated by the cross-hatched area and the ampicillin resistance gene of pBR322 by Ap<sup>r</sup>. Part of the T-region of pGV3839 which is shown in Fig. 12 is shown here; the HindIII fragments (10) and (23) involved in homologous recombination with pAcgB and the apt gene are indicated. Double cross-over events lead to the construction of pGV3850 and another replicon containing the apt gene which is lost.

Fig. 14 illustrates schematically the construction of intermediate cloning vector pGV700 which is given in detail in example 2. The following abbreviations are used to indicate restriction endonuclease sites: B, BamHI; Bg, BglII; E, EcoRI; H, HindIII; S, SalI; Sm, SmaI. The following abbreviations are used to indicate antibiotic resistance: Ap, ampicillin; Cm, chloramphenicol; Sm, streptomycin; Tc, tetracycline. The numbers on the bottom of the figure which refer to TL-DNA indicate the RNA

transcripts of this region (Wilmitzer et al., EMBO J. 1 (1982), 139-146).

Fig. 15 illustrates the structure of the intermediate cloning vector pGV750. Its construction is described in example 2. The restriction endonuclease sites are indicated with their relative locations given in numbers as kilobase pairs (kb). PstI sites are not indicated but there are 3 in the Km<sup>R</sup>/Nm<sup>R</sup> region, and one in the Cb<sup>R</sup> gene. The right and left borders are also indicated. The BglII/BamHI and HpaI/SmaI sites used in the construction of pGV750 are indicated but are not present in pGV750. The shaded area corresponds to TL-DNA, the dark area to the Km<sup>R</sup>/Nm<sup>R</sup> region, the white area to contiguous Ti plasmid sequences, and the line to the cloning vehicle pBR325. Other abbreviations used are : Ocs, octopine synthase; Cm<sup>R</sup>, chloramphenicol resistance; Cb<sup>R</sup>, carbenicillin (analogous to ampicillin) resistance, and Km<sup>R</sup>/Nm<sup>R</sup>, kanamycin resistance/neomycin resistance.

Fig. 16 illustrates the construction of the intermediate vector pGV745 described in detail in example 3. pGV745 is used in the construction of the acceptor plasmid pGV2260, a "B-like" acceptor plasmid shown in Figure 8. Restriction endonuclease sites are indicated as follows : B, BamHI; H, HindIII; R, EcoRI. The ampicillin resistance gene is indicated by Ap<sup>R</sup>. The cross-hatched region indicates DNA homologous to the left side of the T-DNA region of the octopine Ti plasmid and the white region indicates DNA homologous to the right side of the T-DNA region of the octopine Ti plasmid; the physical location and description of the starting plasmids pGV0219 and pGV0120 can be found in De Vos et al., *Plasmid* 6 (1981), 249-253.

Fig. 17 illustrates the construction of the acceptor plasmid pGV2260. The deletion substitution in pGV2217 is indicated as a black box containing the acetyl phosphotransferase gene (indicated apt) which provides resistance to neomycin and kanamycin. The intermediate vector pGV745 (Fig. 16) is depicted in linearized form; it has been opened at the HindIII site of pGV745 shown in Fig. 16. The pBR322 sequence is indicated as a cross-hatched section and the ampicillin resistance gene by Ap<sup>R</sup>. Double cross-over events lead to the construction of pGV2260 and the loss of the apt gene. Restriction endonuclease sites are indicated as follows : B, BamHI; H, HindIII; R, EcoRI.

Fig. 18 illustrates the construction of a plasmid pLGV2381 for the expression of genes downstream of the promoter of the nopaline synthase gene (nos). The 5' and 3' refer to the start and stop of transcription, and the ATG and TAA refer to the codons used to start and stop translation. The heavy black line indicates the nos promoter region, and the white area indicates the nos coding region. Ap<sup>R</sup> denotes ampicillin resistance, and Km<sup>R</sup> kanamycin resistance.

Fig. 19 illustrates the insertion of the plasmid pAGV10 containing the complete octopine synthase (ocs) coding sequence in plasmid pLGV2381 (see also Fig. 18) behind the nos promoter resulting in plasmid pNO1/2. The heavy black lines refer to the promoter regions and the white area to the ocs coding region. Other notations are as in Fig. 18.

Fig. 20 illustrates the nucleotide sequences around the promoter region of the nopaline synthase (nos) gene and the nucleotide sequences around the same region following fusion with the coding region of the octopine synthase gene. The point of fusion is indicated by an asterisk (\*). Several restriction endonuclease sites are indicated. BamHI, HindIII, and SacI. The 5' and 3' refer to the start and stop of transcription. The ATG refers to the first codon used in translation and the TAA refers to the stop codon used in translation. The large arrows indicate the coding regions of the nopaline gene in white and the octopine gene in stripes.

#### Detailed description of the invention

Referring to Fig. 1, we have shown therein a simplified diagram of an acceptor Ti plasmid. This acceptor Ti plasmid contains the two border sequences (1; 2) or regions of the wild-type tumor-inducing (Ti) plasmid. The border sequences are essential for the integration of the T-region of Ti plasmids into a plant cell genome. In other words, they are essential for the integration of any DNA sequence (3) or T-region into a plant cell genome located between these sequences.

The DNA sequence (3) of the acceptor Ti plasmid contains a DNA segment which is homologous with at least a part of a DNA sequence (3') of an intermediate cloning vector illustrated in Figs. 2 and 3. This homology is necessary for co-integration by a single cross-over event (homologous recombination) of the intermediate cloning vector with the acceptor Ti plasmid. The frequency of obtaining cointegrates is determined essentially by the length of the region of homology. In order to effect a homologous recombination event at a good frequency, regions of 1 to 4 kb are normally used (Leemans et al., *J. Mol. Appl. Genet.* 1 (1981), 149-164).

The acceptor Ti plasmid furthermore contains sequences (4) which are essential for the transfer by *Agrobacterium* of the T-region of the Ti plasmids into plant cell genomes.

The construction of such acceptor Ti plasmids and their cointegration with intermediate cloning vectors illustrated in Figs. 2 and 3 will be described later in connection with the discussion of Fig. 4.

In Figs. 2 and 3 we have shown simplified diagrams of intermediate cloning vectors for the cloning of any prokaryotic or eukaryotic gene(s) of interest to be expressed, i.e. transcribed under the control of a promoter and translated in plant cells. These intermediate cloning vectors contain a DNA segment (3') from a cloning vehicle containing a DNA sequence which is homologous with at least a



part of the DNA segment (3) of the acceptor Ti plasmid thus permitting a single cross-over event. Moreover, the intermediate cloning vectors contain at least one gene of interest (5; 7) which contains either its natural or an exogenous promoter sequence. The promoter sequence allows the expression of the inserted gene sequence(s). The use of an exogenous promoter sequence (tailored promoter) may be useful for directing the expression of the inserted gene(s) in a regulated fashion.

Examples of different types of regulation include the following : (i) tissue-specific expression, i.e. leaves, roots, stem, flowers; (ii) level of expression, i.e. high or low; and (iii) inducible expression, i.e. by temperature, light, or added chemical factors.

Examples of genes of interest for the intermediate cloning vectors are : DNA fragments or sequences with the genetic information controlling the synthesis of products such as amino acids or sugars to modify the nutritive or growth potential of a plant; or products which provide protection against external pathogenic agents such as resistance to disease organisms or stressful environmental factors; or products which provide information on basic plant processes which are to be modified by genetic engineering techniques.

Figures 2 and 3 each show intermediate cloning vectors which may contain selectable marker genes (6). Examples of selectable marker genes are those encoding resistance to antibiotics or toxic analogs (for example, amino acid analogs), or genes which can supply a defect in the recipient host cell.

Figure 4 illustrates the structures involved in the construction of hybrid Ti plasmid vectors and Figure 5 describes the actual conjugation steps involved in the isolation of *Agrobacterium* carrying the hybrid Ti plasmid vectors. Since the intermediate cloning vector is constructed in *E. coli* these steps are necessary to transfer the intermediate cloning vector to the acceptor Ti plasmid in *Agrobacterium*.

The known transfer process which was used to prepare modified Ti plasmids in which a portion of the T-region was replaced by an altered sequence involves many steps. Normally, most DNA recombinant manipulations are done in specially designed cloning vehicles such as pBR322 (Bolivar, Gene 2 (1977), 75-93). However, these cloning vehicles cannot transfer on their own to *Agrobacterium*. In the known process this problem is solved by :

a) replacing the pBR cloning vehicle sequence by another wide-host-range cloning vehicle, such as the mini-Sa plasmid (Leemans et al., Gene 19 (1982), 361-384), capable of also replicating in *Agrobacterium*. The manipulations are effected in *E. coli*. An intermediate cloning vector is obtained.

b) Conjugation of the *E. coli* strain carrying the intermediate cloning vector containing the DNA of interest with another *E. coli* strain carrying a helper plasmid which cannot replicate in *Agrobacterium* but which can mediate transfer of itself and other DNAs to *Agrobacterium*.

c) Conjugation of *E. coli* obtained in step (b) with *Agrobacterium* containing a Ti plasmid. The

helper plasmid is lost.

d) Since the intermediate cloning vector is capable of replicating and existing in *Agrobacterium* as a separate replicon, the conjugants obtained in step (c) are a mixture of cells containing either the cointegrate between the intermediate cloning vector and the Ti plasmid or other cells containing the intermediate cloning vector and the Ti plasmid where no cointegration has occurred. In order to specifically isolate only the cointegrates, a second conjugation to another *Agrobacterium* strain without a Ti plasmid must be performed. This transfer is mediated by functions encoded by the Ti plasmid itself. Transfer of the intermediate cloning vector into the second *Agrobacterium* strain is effected only in the form of a cointegrate with the Ti plasmid.

e) In order to obtain the final modified Ti plasmid with the desired replacement a second cross-over event is effected (Leemans et al., J. Mol. Appl. Genet. 1 (1981), 149-164).

The only other known method is essentially the same as outlined above, except that for step (d) another plasmid which is not compatible with the intermediate cloning vector is introduced into *Agrobacterium*; in this case, the cointegration (single cross-over event) can be selected for since all the intermediate cloning vectors which remain as independent replicons will be lost (Matzke et al., J. Mol. Appl. Genet. 1 (1981), 39-49).

We describe a novel and much simplified method for the introduction of intermediate cloning vectors into acceptor Ti plasmids of *Agrobacterium*. Briefly, this method is based on the finding that helper plasmids of *E. coli* allow transfer of many of the commonly used cloning plasmids (such as pBR322) directly to *Agrobacterium*. Since none of these plasmids can replicate in *Agrobacterium* only those which can cointegrate with the acceptor Ti plasmid will be retained. In addition, we use this cointegrate in *Agrobacterium* as a vector composition directly for infection of plant cells. In this manner we have eliminated steps (d) and (e) described above which greatly increases the possibilities for using the acceptor Ti plasmids as vectors for DNA transfer to plant cell genomes by both decreasing the time required for constructing modified hybrid Ti plasmids and increasing the flexibility of the possible constructions.

Thus, as outlined in Figure 5, the introduction of the intermediate cloning vector into the acceptor Ti plasmid is accomplished in two steps. First, conjugation of *E. coli* strain (1) carrying the intermediate cloning vector to another *E. coli* strain (2) carrying two plasmids which will help to mobilize the intermediate cloning vector to *Agrobacterium*. Typical and preferred examples of these helper plasmids are R64dnd11 containing *mob* functions and pGJ28 containing *tra* functions (Finnegan et al., Mol. Gen. Genet. 185 (1982), 344-351). A *bom* site (Warren et al., Nature 274 (1978), 259-261) on the cloning vehicle of the intermediate cloning vector is recognized by the functions encoded by the other two plasmids to allow transfer to occur. All plasmids

should preferably contain antibiotic resistance markers to detect their presence. Secondly, the *E. coli* strain obtained, i.e. the mobilizing strain (3) carrying all three plasmids is conjugated to *Agrobacterium* containing an acceptor Ti plasmid with a region of homology with the intermediate cloning vector. A single cross-over event between the intermediate cloning vector and the acceptor Ti plasmid is detectable by selection for the antibiotic resistance marker of the intermediate cloning vector.

Figure 6 schematically illustrates the DNA molecules used to construct the acceptor Ti plasmid shown in Figure 1. We call this acceptor Ti plasmid (A) to distinguish it from the other acceptor Ti plasmid (B) (Fig. 8). The construction requires a double cross-over event between a Ti plasmid and another plasmid carrying the border sequences (1) and (2) in a cloning vehicle (3). As illustrated in the figure, the cloning vehicle sequence (3) lies between border sequence (1) on the left and (2) on the right; in order to show the correct polarity of the DNA strands, this can be drawn on a circle. However, to show the regions of homology used in the double cross-over event, this circle has been broken as indicated. This is an important subtlety to realize and it is also used in the construction of acceptor Ti plasmid (B) in Figure 8, i.e., if border sequences (1) and (2) were simply inserted within cloning vehicle sequence (3), a double cross-over event would produce a Ti plasmid with a deleted T-region but without the cloning vehicle sequence between the border sequences (1) and (2). As also shown here in Figure 6, the double cross-over event also produces a circular DNA molecule which contains the original T-region between border sequences (1) and (2); as this is not a replicon, it will be lost. Genetic selection for these events can be achieved by, for example, selecting for the loss of an antibiotic resistance marker contained within the T-region of the Ti plasmid and selecting for an antibiotic resistance marker contained within the cloning vehicle sequence (3).

Figure 7 schematically illustrates the construction of an intermediate cloning vector of Figs 2 and 3. A gene of interest (5) and a selectable marker gene (6), each bracketed by a restriction endonuclease site R1 or R2, respectively, are inserted into a cloning vehicle sequence (3') which contains unique restriction sites for enzymes R1 and R2 by digestion and ligation of all molecules. The recombinant DNA molecule obtained is used to transform *E. coli* host cells and transformants are selected for the antibiotic resistance marker ( $Ab^{r1}$ ) of the cloning vehicle sequence (3').

Figure 8 schematically illustrates the DNA molecules used to construct another embodiment of the invention, i.e. acceptor Ti plasmid (B). Here a double cross-over event occurs between a Ti plasmid and a plasmid containing the cloning vehicle sequence (3) between the DNA sequences (9) and (10), which are located just outside the border sequences (1) and (2); in order to illustrate the homologous regions used in the cross-over event the small plasmid has been broken (as in Fig 6). The product of the double cross-over event is acceptor Ti plasmid (B) and

another circular DNA molecule which is lost containing the T-region from the original Ti plasmid plus the DNA sequences (2), (10), (9), and (1). Genetic selection can be achieved as described for Figure 6.

Figure 9 schematically illustrates an intermediate cloning vector to be used in combination with the acceptor Ti plasmid B of Figure 8. Here, the gene of interest (5) is inserted between the border sequences (1) and (2) which are contained in a cloning vehicle sequence (3').

Figure 10 schematically illustrates how a single cross-over event introduces the intermediate cloning vector of Fig. 9 into the acceptor Ti plasmid (B). In this case, selection for the antibiotic resistance marker of the cloning vehicle sequence (3') of the intermediate cloning vector ensures that a hybrid Ti plasmid can be found which is the result of a cointegration between the two plasmids. A hybrid Ti plasmid is produced with the gene of interest contained within the border sequences (1) and (2). The hybrid plasmid thus constructed does not contain in its T-region a sequence which is a direct repeat (as for example the sequences (3) and (3') in hybrid Ti plasmid of Fig. 4, avoiding possible problems of instability of the hybrid vector or of the transformed DNA in the plant cell genome as a result of intramolecular recombination.

Unpublished results from our laboratory also indicate that for construction of the intermediate vector in Fig. 9, it is not essential to have both border sequences 1 and 2; it is sufficient but essential to have at least the right border sequence (2) (see Fig. 1 and Fig. 9). In order to obtain integration of the desired DNA sequence into the plant genome.

Knowledge of the restriction endonuclease maps of the Ti plasmids of *Agrobacterium*, e.g. nopaline or octopine Ti plasmids (Depicker et al., *Plasmid* 3 (1980), 193-211; De Vos et al., *Plasmid* 6 (1981), 249-253), plus the knowledge of the restriction fragments which contain the T-DNA border regions (Zambryski et al., *J. Mol. Appl. Genet.* 1 (1982), 361-370; De Beuckeleer et al., *Mol. Gen. Genet.* 183 (1981), 283-288) enables now any investigator to construct acceptor Ti plasmids according to the process of this invention. The only additional skill required is the ability to perform conventional recombinant DNA techniques and basic bacterial genetic manipulations. The present invention is unique in that it specifically proposes the described acceptor Ti plasmids which have been shown to be effective for the construction of hybrid Ti plasmid vectors; furthermore these acceptor Ti plasmids are designed to form part of a process to introduce genes into the plant cell genome.

In order to further illustrate the disclosed acceptor Ti plasmids, intermediate cloning vectors, hybrid Ti plasmid vectors and vector compositions, and to demonstrate the effectiveness of the vector compositions in providing transformed plant cells and plants showing expression of the foreign gene(s) integrated into the plant cell genome, the following examples are provided.

## Example 1

## Construction of acceptor Ti plasmid pGV3850 (type A)

## Starting strains and plasmids :

*Agrobacterium tumefaciens* (rifampicin-resistant strain C58C1, and chloramphenicol-erythromycin-resistant strain C58C1 derived from wild-type *Agrobacterium*

Ti plasmid = pGV3839

Plasmid of Fig. 11 = pAcgB

The Ti plasmid pGV3839 is constructed from a nopaline plasmid pTIC58tra<sup>c</sup> (pGV3100; Holsters et al., *Plasmid* 3 (1980), 212-230). It contains a deletion substitution mutation near the centre of the T-region; the SmaI fragment 24 internal to HindIII fragment 19 (Depicker et al., *Plasmid* 3 (1980), 193-211) has been substituted by a HindIII fragment of pKC7 (Rao et al., *Gene* 7 (1979, 79-82) which contains the *apt* (acetylphosphotransferase) gene of Tn5. This gene codes for resistance to the aminoglycosides neomycin and kanamycin. Figure 12 gives a restriction map of the T-region of pGV3839.

The plasmid pAcgB is an insert of AcgB in pBR322 which contains only the borders of the T-DNA (see Fig. 11). The borders are defined as the ends of the T-DNA and these regions play a role in the stable integration of the T-DNA into the plant cell genome. The origin and analysis of this clone has been described in detail (Zambryski et al., *Science* 209 (1980), 1385-1391). This clone was obtained by reisolating portions of the T-DNA from transformed tobacco DNA. pAcgB contains the junction of two T-DNA copies which are arranged in tandem so that it contains the left and right borders of the T-DNA. In addition, pAcgB contains the nopaline synthase gene since this genetic information maps very close to the right T-DNA border. The plasmid pAcgB is used for the construction of an "A-like" acceptor Ti plasmid, pGV3850. Figure 6 outlines the structures involved and Figure 13 gives more precisely the regions of DNA involved in the double cross-over events leading to pGV3850.

The described plasmid pAcgB carries a ColE1-specific bom site in the pBR322 portion and can be mobilized from *E. coli* to *Agrobacterium* by using the helper plasmids R64drd11 and pGJ28. The plasmids R64drd11 and pGJ28 contained in *E. coli* are introduced into the *E. coli* strain carrying pAcgB by conjugation. Transconjugants are selected as ampicillin-resistant (from the pBR322 sequences of pAcgB), streptomycin-resistant (from R64drd11) and kanamycin-resistant (from pGJ28) colonies.

The *E. coli* strain carrying all three plasmids is conjugated to *Agrobacterium* strain C58C1 which is rifampicin-resistant and which contains the Ti plasmid pGV3839. The ampicillin-resistance of pBR322 is used to select for the first single cross-over event with the nopaline Ti plasmid. The only way that the ampicillin resistance can be stabilized in *Agrobacterium* is a cross-over event upon homologous

recombination with pGV3839 through one of the homology regions near the T-region borders. By a second cross-over event through the other homology region, the central portion of the T-region of pGV3839 including the *apt* gene (kanamycin resistance) is replaced by the pBR322 sequences of the clone pAcgB. Second recombinants are thus ampicillin-resistant and kanamycin-sensitive. To increase the probability of isolating a second recombinant, the rifampicin-resistant *Agrobacterium* carrying the first recombinant (pAcgB::pGV3839) is conjugated with a second chloramphenicol/erythromycin-resistant *Agrobacterium* strain without a Ti plasmid. In this manner, a chloramphenicol/erythromycin-resistant *Agrobacterium* pGV3850 can be obtained which is ampicillin-resistant and kanamycin-sensitive at a frequency of approximately one in 600 colonies.

Of course, there are other Ti plasmids which can be utilized to construct pGV3850-type acceptor Ti plasmids. Any Ti plasmid carrying a selectable marker gene near the centre of the T-region may be used as a recipient. Furthermore, a pAcgB-like plasmid may be constructed by inserting the T-region border fragments into pBR322 in such a way that the pBR322 sequences lie in-between the left border fragment and the right border fragment in the orientation left border fragment -pBR322 -right border fragment. For example, the left and right border fragments of the nopaline Ti plasmid are HindIII fragment 10 and 23, respectively (Depicker et al., *Plasmid* 3 (1980), 193-211).

A single cross-over event will introduce an intermediate cloning vector containing any gene of interest which is inserted in pBR322 (or its derivatives) into the modified T-DNA region of pGV3850. The only requirement is that the DNA to be introduced contains an additional resistance marker gene to those already found in pBR322 to use as a means to select for the transfer of the intermediate cloning vector from *E. coli* to *Agrobacterium*. This resistance marker can be contained either within the pBR sequences (such as *Cm<sup>r</sup>* for pBR322 or *Km<sup>r</sup>* for pKC7) or within the DNA which is to be tested in the plant cell. In addition, in the acceptor Ti plasmid pGV3850 the *Ap<sup>r</sup>* gene pBR322 can be replaced by another resistance marker gene such as *Km<sup>r</sup>*; in this way even pBR322-containing intermediate cloning vectors which are *Ap<sup>r</sup>* can be directly mobilized to this pGV3850-like acceptor Ti plasmid.

An added advantage of the pGV3850-type acceptor Ti plasmid is that it does not produce tumors in transformed plant cells. Cells which have been "transformed" by pGV3850 can easily be screened from untransformed cells by assaying for the presence of nopaline as the shortened T-DNA region of pGV3850 still contains the gene encoding nopaline synthase. Of course, if the intermediate cloning vector which is co-integrated into the acceptor Ti plasmid pGV3850 contains a marker gene it can also be directly screened or selected for.

Besides insertion of defined intermediate cloning vectors containing a pBR322 sequence by a single cross-over event into the acceptor Ti plasmid pGV3850, this acceptor Ti plasmid can also be used as a recipient for cloned banks of DNA in pBR322 or

its derivatives in a "shotgun"-type experiment. The total population of hybrid plasmid vectors in *Agrobacterium* can be used to infect plant cells and is subsequently screened for expression of any selectable gene(s) of interest. For example, one can easily select for genes encoding amino acid synthesis by applying the total bank to plant cells which are deficient in the chosen amino acid.

The acceptor Ti plasmid pGV3850 has two phenotypic characteristics : (i) the inability to produce tumors, and (ii) the ability to synthesize nopaline if T-DNA transfer occurs into the plant cell genome. Thus, several experiments are performed to check for these characteristics in various plant tissues infected with *Agrobacterium* containing pGV3850.

a) Tests with potato and carrot discs

Inoculation of potato and carrot slices with the acceptor Ti plasmid pGV3850 results in the production of a small amount of callous tissue. This tissue is tested for the presence of nopaline and is found to be positive. It is interesting that this mutant is able to produce small callous tissue; however, it can only be obtained if the discs are grown in media containing low concentrations of both auxins and cytokinins.

b) Inoculation of whole plants with acceptor Ti plasmid pGV3850 Tobacco and petunia plantlets growing on sterile agar media (without hormones) are inoculated with pGV3850. A small amount of tissue growth can only be observed after several months (normally "wild-type" tumors are detected after two weeks). This tissue does not grow on hormone-free media but can be propagated further as sterile tissue culture on media containing both auxin and cytokinin. This tissue is also shown to be nopaline-positive.

c) Furthermore, since pGV3850 "transformed" cells are not tumor-like, these cells are capable of regenerating into normal plants which still contain in their genome the transferred DNA segment. Normal plants will be obtained by culturing the transformed cells on conventional regeneration media (see also example 5).

To prove the usefulness of pGV3850 as an acceptor plasmid the following experiment is performed. An intermediate cloning vector containing oncogenic functions of the octopine T-DNA in pBR325 is recombined into *Agrobacterium* harboring pGV3850. The resulting hybrid Ti plasmid in *Agrobacterium* obtained by a single cross-over event is inoculated onto wounded tobacco plants. Tumor tissue develops after about two weeks. This is evidence that the tumor-inducing DNA is reintroduced into pGV3850 and is expressed properly in transformed plant cells.

Example 2

Construction of intermediate cloning vectors pGV700 and pGV750

An overview of the constructions is represented schematically in figure 14. HindIII fragment 1, representing the right part of TL-DNA of the octopine Ti plasmid B6S3, and present in pGV021 (De Vos et al., Plasmid 6 (1981), 249-253), is inserted first in the HindIII site of the broad-host range vector pGV1122 (Leemans et al., Gene 19 (1982), 361-364). The recombinant plasmid pGV0201 contains the HindIII fragment 1 inserted in the unique HindIII site of the multicopy vector pBR322 (Bolivar et al., Gene 2 (1977), 95-113). pGV0201 and pGV1122 DNA is prepared as described by Betlach et al., Fed. Proc. 35 (1976), 2037-2043. Two µg of pGV0201 DNA are totally digested with 2 units of HindIII (all restriction enzymes are purchased from Boehringer Mannheim) for 1 hour at 37°C in a final volume of 20 µl. The incubation buffer is described by O'Farrell et al., Mol. Gen. Genet. 179 (1980), 421-435. Two µg of pGV1122 DNA are totally digested with HindIII under the same conditions.

One tenth µg of HindIII digested pGV0201 is ligated to 0.05 µg of HindIII-digested pGV1122 with 0.02 units of T4 ligase (Boehringer Mannheim) in a final volume of 20 µl. Incubation buffer and conditions are as recommended by the manufacturer (Brochure "T4 ligase", Boehringer Mannheim, August 1980, #10.M.880.486). Transformation of the ligation mixture into competent *E. coli* K514 hsr<sup>+</sup> cells (Colson et al., Genetics 52 (1965), 1043-1050) is carried out as described by Dagert and Ehrlich, Gene 6 (1980), 23-28. Cells are plated on LB medium (Miller, Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, New York) supplemented with streptomycin (20 µg/ml) and spectinomycin (50 µg/ml). Transformants containing recombinant plasmids are screened for tetracycline sensitivity (10 µg/ml), due to the insertional inactivation of the gene coding for tetracycline resistance (Leemans et al., Gene 19 (1982), 361-364). Streptomycin- and spectinomycin-resistant and tetracycline-sensitive clones are physically characterized. Microscale DNA preparations are performed according to Klein et al. (Plasmid 3 (1980), 88-91). The orientation of the HindIII fragment 1 in the HindIII site of pGV1122 is determined by SalI digestion. Digestion (conditions according to O'Farrell et al., Mol. Gen. Genet. 179 (1980), 421-435) of recombinant plasmids gives 2 fragments after agarose gel electrophoresis. In the α-orientation there are fragments of 0.77 kb and 22.76 kb, whereas in the β-orientation there are fragments of 10.33 kb and 13.20 kb. A recombinant plasmid with the α-orientation is used in subsequent cloning and called pGV1168.

A BglII-SalI fragment containing the left part of the TL-DNA (including the left border sequence) is introduced in pGV1168, cut with BglII-SalI. This fragment is obtained from the recombinant plasmid pGV0153 (De Vos et al., Plasmid 6 (1981), 249-253), containing BamHI fragment 8, from the T-region of pTIB633, inserted in the vector pBR322. pGV0153

and pGV1168 DNA is prepared according to Betlach et al. (Fed. Proc. 35 (1976), 2037-2043). Ten µg of pGV0153 DNA are completely digested with 10 units of BglII and 10 units of SalI for 1 hour at 37°C in final volume of 100 µl. The digestion mixture is loaded on a preparative 0.8% agarose gel. The 2.14 kb BglII-SalI fragment is recovered from this gel by electroelution as described by Allington et al., Anal. Biochim. 85 (1978), 188-196. Two µg of pGV1168 DNA are totally digested by 2 units of BglII and 2 units SalI. One tenth µg of BglII-SalI fragment DNA is ligated to 0.02 µg of BglII-SalI-digested pGV1168 with 0.02 units of T4 DNA ligase in a final volume of 20 µl. The ligation mixture is transformed into competent *E. coli* K514 hsr<sup>-</sup> hsm<sup>+</sup> cells (Dagert and Ehrlich, Gene 6 (1980) 23-28). Cells are plated on LB medium (Miller, Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, New York), supplemented with streptomycin (20 µg/ml) and spectinomycin (50 µg/ml).

Microscale DNA preparations (Klein et al., Plasmid 3 (1980), 88-91) are performed from streptomycin- and spectinomycin-resistant transformants. Recombinant plasmids in which 2.14-kb-BglII-SalI fragment is inserted in BglII-SalI-digested pGV1168 are identified by BglII-SalI digestion, yielding 2 fragments of 2.14 kb and 21.82 kb. A plasmid with a digest pattern corresponding to these molecular weights (2.14 kb and 21.82 kb) is used for further cloning and called pGV1171. A 12.65-kb-fragment from pGV1171 contains the right and left TL-DNA border sequences (De Beuckeleer et al., in Proceedings IVth International Conference on Plant Pathogenic Bacteria, M. Riké (ed.) (1978), I.N.R.A., Angers, 115-126), as well as genes which permit oncogenic proliferation (Leemans et al., EMBO J. (1982), 147-152). This HindIII fragment is inserted into the plasmid pBR325 (Bolivar, Gene 4 (1978), 121-136). pGV1171 and pBR325 are prepared according to Betlach et al., Fed. Proc. 35 (1976), 2037-2043). Two µg of each DNA are totally digested with 2 units of HindIII for 1 hour at 37°C (incubation buffer is described by O'Farrell et al., Mol. Gen. Genet. 179 (1980), 421-435). One tenth µg of HindIII-digested pGV1171 is ligated to 0.05 µg of pBR325, linearized with HindIII, with 0.02 units T4 DNA ligase. Transformation of the ligation mixture in competent *E. coli* K514 hsr<sup>-</sup> hsm<sup>+</sup> is carried out as described by Dagert and Ehrlich, Gene 6 (1980), 23-28. Cells are plated on LB medium (Miller, Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, New York), supplemented with carbenicillin (100 µg/ml). Carbenicillin-resistant clones are screened for sensitivity to tetracycline (10 µg/ml), due to insertional inactivation of the gene coding for tetracycline resistance (Bolivar, Gene 4 (1978) 121-136). Carbenicillin-resistant and tetracycline-sensitive clones are physically characterized by restriction enzyme digestion of DNA prepared from these clones by the microscale technique (Klein et al., Plasmid 3 (1980), 88-91). BamHI digestion gives 4 DNA fragments: in the α-orientation fragments of 0.98 kb, 4.71 kb, 5.98 kb, and 7.02 kb are found whereas the β-orientation gives fragments of 0.98 kb, 4.71 kb, 1.71 kb, and

11.20 kb. A recombinant plasmid corresponding to the α-orientation is obtained, called pGV700, and used for further experiments.

pGV750 is derived from pGV700 by inserting a 2.81 kb BamHI-HpaI fragment coding for kanamycin resistance, for a 3.49-kb-BglII-SmaI fragment, encoding functions essential for oncogenicity, internal to the TL-region inserted in pGV700. The BamHI-HpaI fragment encoding kanamycin resistance is obtained from λ::Tn5 (Berg et al., Proc. Natl. Acad. Sci. USA 72 (1975), 3628-3632). Preparation of λ::Tn5 is as described (Miller, Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, New York). pGV700 DNA is prepared according to Betlach et al. (Fed. Proc. 35 (1976), 2037-2043). Two µg of pGV700 DNA are totally digested with 2 units of BglII and 2 units SmaI. Two µg of λ::Tn5 DNA are totally digested with 2 units of BamHI and 2 units HpaI. One µg of BamHI-HpaI digested λ::Tn5 is ligated to 0.2 µg BglII-SmaI-digested pGV700 with 0.5 units of T4 DNA ligase in a final volume of 10 µl (conditions are as recommended by the manufacturer). The ligation mixture is transformed in competent *E. coli* K514 hsr<sup>-</sup> hsm<sup>+</sup> cells (Dagert and Ehrlich, Gen 6 (1980) 23-28). Cells are plated on LB medium (Miller, Experiments in Molecular Genetics (1972), Cold Spring Harbor Laboratory, New York), supplemented with carbenicillin (100 µg/ml) and kanamycin (25 µg/ml). Cb<sup>R</sup> and Km<sup>R</sup> clones are physically characterized by restriction enzyme analysis of DNA prepared according to the microscale technique (Klein et al., Plasmid 3 (1980), 88-91). BglII/BamHI double digests of this DNA gives 3 fragments of 3.94 kb, 5.89 kb, and 8.09 kb, whereas HindIII digests yields 3 fragments of 2.68 kb, 5.99 kb, and 9.25 kb. A plasmid showing these digestion patterns is called pGV750 and is illustrated schematically in Figure 17.

pGV700 and pGV750 are two different intermediate cloning vectors which contain the left and right border sequences of TL-DNA of the octopine T1 plasmid pTiB6S3; in addition, the internal T-region is deleted to different extents in each of the two plasmids. pGV700 contains a shortened T-region with genetic information for octopine synthase (transcript 3), and 3 other products, 4, 6a, and 6b (see Willmitzer et al., EMBO J. 1 (1982), 139-146, for a description of T-region products). The combination of these three products (4, 6a, 6b) will cause shoot formation in transformed plants. pGV750 contains even less of the T-region, i.e. only the octopine synthase gene. The information for products 4, 6a, and 6b has been substituted by the antibiotic resistance marker gene encoding kanamycin (neomycin) resistance.

pGV700 and pGV750 are examples of intermediate cloning vectors which can be used with acceptor T1 plasmids of the B-type (see Fig. 8 and example 3 below); these vectors are partially analogous to the one shown in Fig. 9 except that they do not contain a gene of interest. A gene of interest can be easily inserted into these vectors as they contain single restriction endonuclease sites for cloning within their modified T-regions (see Figs. 14 and 15).

## Example 3

## Construction of acceptor TI plasmid pGV2260 (type B)

Starting strains and plasmids :  
*Agrobacterium tumefaciens* (rifampicin-resistant strain C58C1 and erythromycin-chloramphenicol-resistant strain C58C1, derived from wild-type *Agrobacterium*)

TI plasmid = pGV2217

Intermediate vector (Fig. 16) = pGV745

The construction of the TI plasmid pGV2217 has been described in detail (Leemans et al., EMBO J. 1 (1982), 147-152). It contains a deletion substitution mutation of the entire TL-region of the octopine TI plasmid : the BamHI fragments 8, 30b, 28, 17a and the left 3.76 kb BamHI-EcoRI fragment of the BamHI fragment 2 (De Vos et al., Plasmid 6 (1981), 249-253) have been substituted by an EcoRI-BamHI fragment of pKC7 (Rao & Rogers, Gene 7 (1979), 79-82) which contains the apt (acetyl phosphotransferase) gene of Tn5. This gene codes for resistance to the aminoglycosides, neomycin and kanamycin.

The construction of the intermediate vector pGV745 is represented schematically in Fig. 16 and is described as follows. The recombinant plasmid pGV713 was derived from the octopine TI plasmid subclone pGC0219 (De Vos et al., Plasmid 6 (1981), 249-253), containing HindIII fragment 14, 18c, 22a and 38c in  $\alpha$ -orientation. pGV0219 DNA was digested to completion with BamHI and subsequently ligated under conditions which favour self ligation of the plasmid (final concentration of DNA in ligation mixture < 1  $\mu$ g DNA/ml). Transformants were selected for ampicillin resistance, and physically characterized by restriction enzyme digestion. A clone, which no longer contains the 6.5 kb BamHI fragment present in pGV0219, was isolated and called pGV713. This clone pGV713 was used in subsequent cloning (see below). The recombinant plasmid pGV738 was derived from pGV0120 (De Vos et al., Plasmid 6 (1981), 249-253), containing BamHI fragment 2. pGV0120 DNA was digested with EcoRI and self-ligated (as above for the construction of pGV713). Transformants were selected for ampicillin resistance and analyzed by restriction enzyme digestion. A clone in which EcoRI fragments 20, 12, and a 2.95 kb EcoRI fragment containing part of EcoRI fragment 19a and part of pBR322 were deleted, was used in further cloning and called pGV738. This plasmid still contains a 5.65 kb EcoRI-BamHI fragment from the right part of BamHI fragment 2 (De Vos et al., Plasmid 6 (1981), 249-253).

Next, pGV713 DNA was digested with HindIII and BamHI, and the digest was applied onto a preparative agarose gel. After electrophoresis the 2.30 kb HindIII-BamHI fragment, contained within pGV713, was purified by electroelution (as described by Allington et al., Anal. Biochem. 85 (1975), 188-196). This fragment was ligated to pGV738, digested to completion with HindIII and BamHI. After

transformation, ampicillin-resistance clones were physically characterized by restriction enzyme digestion. For example, EcoRI-BamHI digestion should give 2 fragments of respectively 3.98 kb (= vector part) and 7.95 kb (= insert part). A recombinant plasmid with these characteristics was called pGV745 and used as intermediate vector for the construction of the acceptor TI plasmid pGV2260.

The plasmid pGV745 contains a ColE1-specific *ori* site in the pBR322 portion and can be mobilized from *E. coli* to *Agrobacterium* by using the helper plasmids R64drd11 and pGJ28, as described in example 1 (construction of the acceptor TI plasmid pGV3850).

pGV745 was mobilized to *Agrobacterium* strain C58C1 which is rifampicin-resistant and contains the TI plasmid pGV2217. The first cross-over event was selected by using the ampicillin resistance of pBR322 in the same way as described in example 1 (the construction of the acceptor TI plasmid pGV3850). By a second cross-over event the deletion substitution mutation present in pGV2217 is replaced by the pBR322 sequences of the plasmid pGV745. Second recombinants were picked up by directly screening the ampicillin-resistant transconjugants, which resulted from coinfection of pGV745 with pGV2217, for the loss of kanamycin resistance. In this way, a rifampicin *Agrobacterium* strain C58C1, containing pGV2250 (ampicillin-resistant, kanamycin-sensitive), was obtained.

This TI plasmid pGV2260 will be used as an acceptor plasmid (type B) for intermediate cloning vectors of the pGV700- or pGV750-type. These are composed of (i) a DNA fragment carrying the ampicillin resistance gene, the origin of replication and the *ori* site of pBR322; (ii) a DNA fragment containing the left and right border sequences of the TL-DNA, and an additional resistance marker to those already present on pBR322, which will enable the genetic selection for the transfer of the intermediate cloning vector from *E. coli* to *Agrobacterium* as well as for its coinfection in the acceptor TI plasmid pGV2260.

For example, we have been able to show that *Agrobacterium* carrying a cointegrate between pGV2260 and pGV700 is capable of transferring the expected DNA sequences (those contained between the T-DNA borders) to plant cell genome. The transformed plant cells exhibit the expected phenotype i.e. tumors which produce shoots, given that pGV700 contains the genetic information for three products (4, 6a, 6b; see Willmitzer et al., EMBO J. 1 (1982), 139-146). In this manner we have shown that an acceptor TI plasmid of the B-type is capable of transferring DNA to plant cells when used as a cointegrate with an intermediate cloning vector of the type illustrated in Fig. 9 and given in example 2.

## Example 4



# Construction of an intermediate cloning vector containing a gene to be expressed in plants

Until the present invention, insertion of whole genes into more or less random positions within the T-region of TI plasmids has not resulted in expression of the foreign sequence following transfer to the plant genome. According to the process of this invention, the coding region of (any) foreign gene(s) of interest is linked to transcriptional initiation and termination signals which are known to be functional in the plant cell. The usefulness of this approach is demonstrated according to the present invention by experiments involving the DNA sequences encoding the nopaline synthase gene. The entire sequence of this gene and the exact start and stop of transcription are known (Depicker et al., *J. Mol. Appl. Genet.* 1 (1982), 561-574). According to the present invention, the protein-coding region of any foreign gene can be inserted adjacent to the *nos* promoter. As an example of a foreign gene sequence, the coding region of the octopine synthase gene (De Greve et al., *J. Mol. Appl. Genet.* 1 (1982), 499-512) is inserted adjacent to the *nos* promoter. This construction is mobilized into an acceptor TI plasmid and used to infect plants. The resulting tumor tissue is assayed for the presence of octopine, and is found to be positive.

The construction of the intermediate cloning vector containing the chimeric nopaline promoter : octopine synthase structural gene is shown and described in figures 18 to 20.

Briefly, the restriction fragment HindIII-23 containing the *nos* gene is engineered *in vitro* to remove most the *nos* coding sequence, and retain the *nos* promoter adjacent to the restriction endonuclease site BamHI (Fig. 18). Ten µg of pGV0422 (a pBR322 derivative carrying the HindIII-23 fragment which contains the complete *nos* gene; Depicker et al., *Plasmid* (1980), 193-211) are digested with *Sau*3A and the 350 bp fragment carrying the *nos* promoter is isolated from a preparative 5% polyacrylamide gel. The promoter fragment is ligated to *Bgl*II-cut pKC7 (Rao et al., *Gene* 7 (1979), 79-82) previously treated with bacterial alkaline phosphatase (BAP) to remove 5'-terminal phosphate groups. Twenty µg of the resulting plasmid (pLGV13) are digested with *Bgl*II and treated with 7 units of the *Bal*31 exonuclease (Biolabs, New England) for 4 - 10 minutes in 400 µl of 12 mM MgCl<sub>2</sub>, 12 mM CaCl<sub>2</sub>, 0.8 M NaCl, 1 mM EDTA, and 20 mM Tris-HCl, pH 8.0, at 30°C. During this time approximately 20 - 50 bp of DNA are removed. The *Bal*31-treated molecules are digested with *Bam*HI, and incubated with the Klenow fragment of DNA polymerase and all four deoxynucleoside triphosphates (at 10 mM each) to fill in the ends. Plasmids are screened for a regenerated *Bam*HI site derived from the ligation of a filled-in *Bam*HI end and the end of the *Bal*31 deletion. The sizes of the *Bam*HI-SacII fragment of several candidates are estimated in a 6% urea-polyacrylamide gel, and the nucleotide sequences of the candidates with sizes ranging between 200 - 280 nucleotides are determined. The clone pLGV81 containing the *Sac*II-

*Bam*HI fragment of 203 bp carrying the promoter is used to substitute the *Sac*II-*Bam*HI fragment in the *nos* gene in pGV0422; the final promoter vector is called pLGV2381. All the recombinant plasmids are selected by transformation of the *E. coli* strain HB101.

The plasmid vector containing the engineered *nos* promoter is digested with *Bam*HI and the coding sequence for *ocs* which is contained on a *Bam*HI fragment is inserted into this site. The *ocs* coding sequence is also engineered *in vitro* to be bracketed by the *Bam*HI restriction endonuclease site as described in Fig. 19. Ten µg of *Bam*HI fragment 17a of the octopine TI plasmid B6S3 (De Vos et al., *Plasmid* 6 (1981), 249-253) are digested with *Bam*HI and *Sma*I, the fragment containing the *ocs*-coding sequence isolated from a 1% agarose gel, and ligated to the large *Bam*HI-PvuII fragment of pBR322; 20 µg of the resulting plasmid, pAGV828, is digested with *Bam*HI, treated with the exonuclease *Bal*31 as described in Figure 18, subsequently digested with *Hind*III, and the ends are filled-in and self-ligated. The sizes of the *Bal*31 deletions are estimated in a 6% polyacrylamide gel. The nucleotide sequences of several candidates are determined, and a candidate having only 7 bp remaining of the 5'-untranslated leader sequence is chosen for further work (pOCSA). In order to bracket the *ocs* sequence with *Bam*HI sites, the *Cla*I-*Rsa*I fragment is filled-in and subcloned into the *Bal* site of pLC236 (Remaut et al., *Gene* 15 (1981), 81-93). The resulting plasmid pAGV40 is digested with *Bam*HI, the fragment carrying the *ocs* sequence isolated by electroelution from a preparative 1% agarose gel, and ligated to pLGV2381 previously cut with *Bam*HI, and treated with BAP (bacterial alkaline phosphatase). The insertion of the *ocs* sequence in pLGV2381 is obtained in both orientations (pNO-1 and pNO-2).

The nucleotide sequences showing the exact junction point in the *nos:ocs* fusion are shown in Fig. 20.

Further, the plasmid vector containing the engineered *nos* promoter is used to insert DNA from the plasmid R67 which encodes the enzyme dihydrofolate reductase. The coding sequence containing the dihydrofolate reductase gene is contained on a *Bam*HI fragment as described (O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78 (1981), 1527-1531), and thus is easily inserted into the *nos* promoter vector containing the *Bam*HI site adjacent to the promoter region as described above. This gene is an example of a selectable marker gene (see for example Figs. 2, 3, 4, 5, and 7) since when expressed it provides resistance to the antibiotic methotrexate. When this intermediate cloning vector is mobilized into an *Agrobacterium* containing a wild-type nopaline acceptor TI plasmid, a single cross-over event occurs and a hybrid TI plasmid vector is obtained. The vector composition is used to infect plants. The resulting tumor tissue is found to be capable of sustained growth in the presence of 0.5 µg/ml methotrexate.

The construction of the intermediate cloning vectors containing the *ocs* and dihydrofolate reduc-

tase coding regions behind the *nos* promoter described above, and their transfer and expression in transformed plant cells following cointegration with the Ti plasmid of *Agrobacterium* provides evidence that foreign genes can be transferred and expressed in plant cells according to the processes of this invention.

#### Example 5

Isolation of plant cells and plants containing the desired gene(s) inserted in their chromosomes

We have obtained plant cells and whole plants transformed with non-oncogenic acceptor Ti plasmid derivatives (e.g. pGV3850) using any of the following three methods:

- (1) inoculation *in vivo* of whole plants followed by subsequent culture *in vitro* on media which allow the regeneration of shoots;
- (2) coinfection *in vivo* of whole plants in the presence of other *Agrobacterium* strains which directly induce shoots at the wound site;
- (3) cocultivation *in vitro* of single plant cell protoplasts.

We will described each of these methods below.

The first method is based on a modification of methods normally used to obtain infection of whole plant tissues with wild-type *Agrobacterium* strains which results in the production of crown gall tissues. Since pGV3850 is a non tumor-producing (nonon-cogenic) *Agrobacterium* derivative, no tumorous growth is observed at the infected site. However, if the infected tissue is removed and propagated in tissue culture, transformed tissues can easily be obtained. After an initial culture period (simple to increase the mass of the tissue) the wound site tissue is grown under conditions which allow shoots to form. Both untransformed and pGV3850-transformed cells will produce shoots. The transformed shoots can easily be distinguished by a simple assay for the presence of nopaline.

We have obtained pGV3850-transformed calli and shoots derived from decapitated tobacco plantlets of *Nicotiana tabacum* Wisconsin 38 using the following protocol (all manipulations are done under sterile conditions in a laminar flow hood).

- (1) Use 6-week old tobacco seedlings grown in small jars (10 cm diameter x 10 cm height) on solid Murashige & Skoog (MS) medium (Murashige and Skoog, *Physiol. Plant.* 15 (1962) 473-497) containing 0.8% agar.

- (2) Remove youngest top leaves with a scalpel and discard.

- (3) Inoculate wound surface with a spatula or toothpick containing *Agrobacterium* derived from a fresh plate culture grown under selective conditions (e.g. for the rifampicin-resistant, ampicillin resistant *Agrobacterium* strain containing Ti plasmid pGV3850, YEB medium containing 100 µg/ml rifampicin and 100 µg/ml carbenicillin are used; YEB medium : 5 g/l

Bacto beef extract, 1 g/l Bacto yeast extract, 5 g/l peptone, 5 g/l sucrose,  $2 \times 10^{-3}$  M  $\text{MgSO}_4$ , pH 7.2, and 15 g/l agar). Inoculate at least 8 plantlets for each pGV3850 construction.

- (4) Incubate 2 weeks; there should be little or no response at the site of inoculation; sometimes very tiny calli appear.

- (5) Remove a thin section less than 1 mm thick from the wound surface.

Incubate wound surface on a plate containing Linsmaier & Skoog (LS) agar medium (Linsmaier and Skoog, *Physiol. Plant.* 18 (1965) 100-127) with auxins and cytokinins (1 mg/l NAA, 0.2 mg/l BAP) and 1% sucrose.

- (6) After about 6 weeks callus should be large enough, about 5 mm diameter at least, to test a portion for the presence of nopaline. Not all wound calli produce nopaline; approximately one in four plants produce a nopaline-positive wound callus.

- (7) Transfer nopaline-positive calli to agar plates containing regeneration medium : LS medium as above + 1% sucrose and 1 mg/l BAP cytokinin.

- (8) Good-sized shoots (1 cm high) appear after about 4-6 weeks. Transfer the shoots to fresh agar plates containing LS medium + 1% sucrose without hormones to allow further growth and root formation.

- (9) Let shoots grow 1 or 2 weeks such that a portion (one or two small leaves) can be removed to test for the presence of nopaline.

- (10) Transfer nopaline-positive shoots to larger vessels (10 cm jars as above containing MS medium as in (1) to grow further.

N.B. All plant culture media for infected tissues contain 500 µg/ml of the antibiotic cefotaxime (Claforan®, Hoechst) as a selection against *Agrobacterium* containing pGV3850. This drug works well to prevent growth of all *Agrobacterium* (including those which are carbenicillin-resistant).

Another method to obtain transformed and shooting tissues has been recently developed in our laboratory. This method is based on the observation that certain mutant Ti plasmid strains of *Agrobacterium* induce crown gall tumors which produce shoots. Such shoot-inducing (shi) mutants map to a particular region of the T-DNA (transferred DNA segment) of the Ti plasmids of *A. tumefaciens* (Leemans et al., *EMBO J.* 1 (1982) 147-152; Joos et al., *Cell* 32 (1983) 1057-1067). Often the induced shoots are composed of completely normal untransformed cells. Thus, we tried to inoculate plants with a mixture of two different *Agrobacterium*, one carrying an octopine Ti plasmid shooter mutant and the other carrying pGV3850. In this manner, there is a good chance that the octopine shooter mutation can induce shoots which have been transformed with pGV3850. We have inoculated plants with *Agrobacterium* containing Ti plasmid pGV3850 and an octopine shoot inducing Ti plasmid in a 5:1 ratio. In this way we have obtained pGV3850-transformed shoots; these shoots are easily screened by assaying for the presence of nopaline. This method avoids the need for any elaborate tissue culture



methods. The nopaline-positive shoots are transferred to media containing simple salts and sugar with any growth-regulating hormones to allow further growth. After the shoots have reached a sufficient size they can easily be transferred to soil for propagation. This coinfection procedure should be particularly useful for transforming plant species which are not readily amenable to tissue culture. Thus, a whole range of agronomically and economically important plants, such as legumes, medicinal plants, and ornamentals will be able to be engineered by *Agrobacterium*.

The third procedure allows the isolation of *Nicotiana tabacum* protoplasts and the selection of hormone-independent T-DNA-transformed cell clones after co-cultivation of the protoplast-derived cells with oncogenic *Agrobacterium* strains. An analogous technique can be used for the selection of transformed cells when other dominant selective markers are used, such as antibiotic resistance genes constructed in such a way as to be expressed in higher plant cells (see example 3).

In this case, however, the conditions for selection have to be optimized in each case (concentration of the selective agent, time between transformation and selection, concentration of the protoplast-derived cells or cell colonies in the selective medium). If no selection for the transformed cells is possible, e.g. because avirulent T-DNA mutants are used, such as e.g. pGV3850 or pGV2217 (Leemans et al., EMBO J 1 (1982), 147-152), it is possible to cultivate the cells after genetic transformation on auxin- and cytokinin-containing medium (e.g. Murashige and Skoog medium (Murashige and Skoog, *Physiol. Plant* 15 (1982), 473-497) with 2 mg/litre NAA ( $\alpha$ -naphthalene acetic acid) and 0.3 mg/litre kinetin), and to identify the transformed colonies by their opine content. In this way, after electrophoretic analysis for agropine and mannopine synthesis (method see Leemans et al., *J. Mol. Appl. Genet.* 1 (1981), 149-164) about 660 colonies can be found, obtained after infection with pGV2217, a *Nicotiana tabacum* SR1 cell line which synthesizes the TR-encoded opine mannopine ( $N^2$ -(1-mannityl)-glutamine). Numerous shoots are formed after incubation of callus pieces of this cell line on regeneration medium (Murashige and Skoog medium with BAP (6-benzylaminopurine) (1 mg/litre) as the sole plant growth regulator). All 20 shoots analyzed are still able to synthesize mannopine. After transfer onto hormone-free Murashige and Skoog medium, the shoots grow as morphologically normal tobacco plants still containing mannopine.

The protoplast isolation and transformation described here for *N. tabacum* can also be used for *N. plumbaginifolia*.

## 2. Experimental procedures

### 2.1 Shoot culture conditions

*Nicotiana tabacum* shoot cultures are maintained in 250 ml glass jars on hormone-free Murashige and Skoog medium (Murashige and Skoog, *Physiol. Plant* 15 (1982), 473-497) under sterile conditions in a culture room (16 hour day, 1500 lux white

fluorescent light ("ACEC LF 58 W/2 4300°K Economy"), 24°C, 70% relative humidity). Five week old shoot cultures are used for protoplast isolation.

### 2.2 Protoplast isolation

Aseptic techniques are used for all steps in protoplast isolation and culture. The protoplasts are isolated by a mixed enzyme procedure. All leaves, except for very young leaves smaller than 2 cm, can be used for protoplast isolation. The leaves are cut in strips, about 2 - 3 mm wide, with a sharp scalpel knife. Two to three grams of leaf material is incubated 18 hours at 24°C in 50 ml enzyme mixture in the dark without agitation. The enzyme mixture consists of 0.5% cellulase Onozuka R-10 and 0.2% macerozyme Onozuka R-10 in hormone-free K3 medium (Nagy and Maliga, *Z. Pflanzenphysiol.* 78 (1976), 453-455). The mixture is filter-sterilized through a 0.22  $\mu$ m pore membrane, and can be stored for at least 6 months at -20°C without notable loss of activity.

### 2.3 Protoplast culture

After 18 hours incubation the mixture is agitated gently in order to release protoplasts. The mixture is subsequently filtered through a 50  $\mu$ m sieve, and the filtrate is transferred to 10 ml centrifuge tubes. After centrifugation for 6 minutes at 60 - 80 g in a swinging bucket rotor the protoplasts form a dark green floating band. The liquid underlying the protoplasts, and the debris which forms the pellet, are removed using a capillary tube connected to a peristaltic pump. The protoplasts are pooled in one tube and washed 2 times with culture medium. The culture medium is the K3 medium (Nagy and Maliga, *Z. Pflanzenphysiol.* 78 (1976), 453-455) with NAA (0.1 mg/litre) and kinetin (0.2 mg/litre) as growth regulators. The medium is adjusted to pH 5.6 and sterilized through 0.22  $\mu$ m filter membrane. After the second wash, the protoplasts are counted using a Thoma hemacytometer (obtained from "Assistant", F.R.G.), and resuspended in culture medium at a final density of  $10^5$  protoplasts/ml. The protoplasts are cultured in a volume of 10 ml per 9 cm diameter tissue culture quality petri dish. The dishes are sealed with Parafilm® and incubated for 24 hours in the dark, and thereafter in dim light (500 - 1000 lux) at 24°C.

### 2.4 Transformation by co-cultivation

The protoplast cultures are infected 5 days after isolation. *Agrobacterium* cultures are grown for 18 hours in liquid LB medium (Miller, *Experiments in Molecular Genetics* (1972), Cold Spring Harbor Laboratory, New York), and resuspended in K3 culture medium at a density of  $2 \times 10^9$  cells/ml. Fifty  $\mu$ l of this suspension is added to the plant protoplast cultures and after sealing with Parafilm®, the cultures are incubated under the same conditions as described under 2.3. After 48 hours the cultures are transferred to 10 ml centrifuge tubes and centrifuged in a swinging bucket rotor at 60 - 80 g for 6 minutes. The floating band and pellet are pooled and resuspended in 10 ml of K3 medium (Nagy and Maliga, *Z. Pflanzenphysiol.* 78 (1976), 453-455) supplemented with an antibiotic (carbenicillin 1000

µg/ml or cefotaxime 500 µg/ml).

After two weeks of incubation, the protoplast-derived micro-calli are centrifuged and resuspended in K3 medium (Nagy and Mailga, *Z. Pflanzenphysiol.* 78 (1976), 453-455) with the same growth regulator and antibiotic concentrations as before, but 0.3 M sucrose instead of 0.4 M. The cell density in this medium is adjusted to about  $2.5 \times 10^3$  micro-calli per ml.

After two weeks of incubation under the same conditions the calli are transferred to K3 medium with the same antibiotic concentrations as before, but with reduced sucrose (0.2 M) and growth regulators (NAA 0.01 mg/litre and kinetin 0.02 mg/litre).

After two to three weeks of incubation, the putative transformants can be recognized by their light green and compact aspect, and better growth. These colonies are then transferred to hormone-free Linsmaler and Skoog medium (Linsmaler and Skoog, *Physiol. Plant.* 18 (1965), 100-127) solidified with 0.6% agar and containing reduced antibiotic concentrations (carbenicillin 500 µg/ml or cefotaxime 250 µg/ml).

Opine tests can be done on the putative transformants which grow on this hormone-free medium when they reach 3-4 mm in diameter. Half of each colony is used for the detection of octopine and nopaline (Aerts et al., *Plant Sci. Lett.* 17 (1979), 43-50) or agropine and mannopine (Leemans et al., *J. Mol. Appl. Genet.* 1 (1981), 149-164). This test allows to confirm the transformed nature of the colonies selected on hormone-free medium. Afterwards, the selected colonies can be cultured on antibiotic-free medium.

#### 2.5 Co-cultivation without selection on hormone-free media

When selection for transformed cells is not possible (e.g. because avirulent T-DNA mutants are used) or is not required because a dominant selectable marker such as an antibiotics resistance gene is present in the T-DNA, the treatment of the protoplast-derived cells can be simplified (the hormone reduction steps are no longer necessary). The protoplasts are treated as described previously until the infection step. Forty-eight hours after addition of the bacteria the protoplast-derived cells are centrifuged (8 minutes, 60-80 g), and resuspended in medium AG (Caboche, *Planta* 149 (1980), 7-18) which is able to support cell growth at very low density. The cells are counted using a Fuchs-Rosenthal counting chamber (obtained from "Assistant", F.R.G.), and resuspended at the density required for subsequent work. If the colonies must be manipulated individually for opine tests, plating at low cell density (100 protoplast-derived cells and cell colonies per ml) gives large cell colonies after one month of incubation. If drug selection for the transformed cells is possible, the cells are incubated at a higher density ( $10^3$  -  $10^4$ /ml), and the selective agent used is added to the medium in a concentration and at a time which has to be optimized for each type of selection.

#### 2.6 Regeneration of whole plant from callous tissue

Normal plants are easily obtained from callous tissue (for example either derived from protoplast transformation or from whole plant inoculation (see 2.7). The callous tissue is grown on Murashige and Skoog medium containing 1 mg/ml BAP; this medium induces shoot formation after 1-2 months. These shoots can be transferred to medium without hormones so that roots form and a complete plant is produced.

#### 2.7. Tumor induction on tobacco seedlings

Tobacco seeds (e.g. cultivar Wisconsin 38) are surface sterilized by treatment with : 70% denaturated ethanol/H<sub>2</sub>O for 2 minutes; followed by 10% commercial bleach and 0.1% sodium dodecyl sulfate (SDS); further rinsed 5 times with sterile H<sub>2</sub>O.

The sterile seeds are sown in large (25 mm wide) test tubes containing the salts of Murashige and Skoog medium solidified with 0.7% agar and covered with polycarbonate tops. Then the tubes are incubated in culture room (12,000 lux, 16 hours light/8 hours dark; 70% relative humidity; 24°C). After 4-6 weeks the plants are ready to use. They remain optimal for at least another month.

Plantlets should be at least 3 cm high and have four or more leaves. The plants are then decapitated transversally through the youngest internode with a new sterile scalpel blade; the upper part of the plant removed from the tube, and bacteria from an agar plate culture applied on the wound surface with a flamed microspatula.

Tumors appear after 2 weeks for the wild-type and after a longer time for some of the attenuated mutant strains. This method is used inoculate tobacco (*Nicotiana tabacum*), *Nicotiana glauca* and *Petunia hybrida*.

#### Concluding remarks

The present invention offers for the first time the possibility to transform plants with *Agrobacterium* harboring a hybrid T1 plasmid vector which lacks the oncogenic functions of the T-region of wild-type T1 plasmids. Since the influence of the oncogenic functions of the T-region on the transfer of DNA from the T1 plasmid to plant cells was not known, it is surprising that nevertheless transfer of the modified T-region containing (a) gene(s) of interest to plant cells occurs. There is cointegration and stable maintenance of this transferred DNA in the plant cell genome. Furthermore, expression of chosen gene(s) of interest can be achieved provided the gene(s) either contain - or are constructed to contain - suitable promoter sequences. The concept of effecting a single cross-over event between an intermediate cloning vector containing the chosen gene(s) of interest with an especially designed acceptor T1 plasmid greatly simplifies the construction of any hybrid T1 plasmid vector useful for the transformation of plant cells. The especially designed acceptor T1 plasmids contain the DNA segment of a conventional cloning vehicle such that any gene(s) of interest (which has been inserted into the same or a related cloning vehicle as part of an intermediate cloning vector) can form a cointegrate

by a single cross-over event. The two segments of the cloning vehicle(s) provide the necessary regions of homology for recombination.

Microorganisms and intermediate cloning vectors, acceptor TI plasmids and hybrid plasmid vectors prepared by the processes of this invention are exemplified by cultures deposited in the German Collection of Microorganisms (DSM), Göttingen, on December 21st, 1983, and identified there as:

(1) intermediate vector plasmid pAcgB in *Escherichia coli* K12 HB101;

(2) *Agrobacterium tumefaciens* C58C1 rifampicin-resistant strain carrying carbenicillin-resistant acceptor TI plasmid pGV3850;

(3) intermediate vector plasmid pGV700 in *Escherichia coli* K12 strain K514 (thr leu thi lac hsdR);

(4) intermediate vector plasmid pGV750 in *Escherichia coli* K12 strain K514 (as above in (3));

(5) *Agrobacterium tumefaciens* C58C1 rifampicin-resistant strain carrying carbenicillin-resistant acceptor TI plasmid pGV2260;

(6) intermediate vector plasmid pNO-1 carrying the octopine synthase coding region under the control of the nopaline promoter, in *Escherichia coli* K12 HB101;

(7) strain used in mobilization of intermediate vectors to *Agrobacterium* = GJ23 carrying mobilizing plasmids pGJ28 and R64drd11 (Van Haute et al., EMBO J. 2 (1983), 411-418); GJ23 is *Escherichia coli* K12, JC2926, a *recA* derivative of AB1157 (Howard-Flanders et al., Genetics 49 (1964), 237-246).

These cultures were assigned accession numbers 2792 (1), 2798 (2), 2796 (3), 2797 (4), 2799 (5), 2833 (6), and 2793 (7), respectively.

While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic constructions can be altered to provide other embodiments which utilize the processes and compositions of this invention.

#### Claims

1. A non-oncogenic TI plasmid vector system free of T-DNA genes controlling neoplastic growth of transformed plants which comprises:

(a) DNA sequences coding for functions which are essential for the transfer of the T-region of a wild-type TI plasmid by *Agrobacterium* into a plant genome; and

(b) at least one gene of interest which has been inserted into said vector system and which is capable of being expressed in plants which are susceptible to infection by *Agrobacterium*, said gene being under the control of at least one promoter capable of directing the expression of said gene in the plant and associated with at least the right border sequence of the T-region of a

wild-type TI plasmid, said border sequence allowing the integration of said gene into the plant genome.

2. The TI plasmid vector system according to claim 1, wherein said gene(s) or interest is (are) under the control of its (their) natural promoter.

3. The TI plasmid vector system according to claim 1, wherein said gene(s) of interest is (are) under the control of a promoter which is exogenous with respect to the gene(s) of interest.

4. An intermediate cloning vector comprising (a) a cloning vehicles segment (3') containing the right border sequence of the T-region of a wild-type TI plasmid (2) and a DNA sequence which is homologous with a DNA sequence in an acceptor TI plasmid; and

(b) at least one gene of interest (5) under the control of a promoter capable of directing gene expression in plants which is associated with said border sequence in a manner allowing its integration into the plant genome.

5. The intermediate cloning vector according to claim 4, containing additionally at least one selectable marker gene, adjacent to the gene(s) of interest (5).

6. The intermediate cloning vector according to claim 4, wherein the gene(s) of interest (5) is (are) under the control of its (their) natural promoter.

7. The intermediate cloning vector according to claim 4, wherein the gene(s) of interest (5) is (are) under the control of a promoter which is exogenous with respect to the gene(s) of interest.

8. A process for the preparation of a hybrid TI plasmid vector which comprises mobilizing the intermediate cloning vector according to any one of claims 4 to 7 in the presence of helper plasmids to an *Agrobacterium* containing an acceptor TI plasmid and allowing a coinfection to proceed between the intermediate cloning vector and the acceptor TI plasmid by a single cross-over event.

9. A non-oncogenic hybrid TI plasmid vector between an acceptor TI plasmid and an intermediate cloning vector according to any one of claims 4 to 7, comprising:

(a) the right border sequence (2) of the T-region of the wild-type TI plasmid;

(b) non-oncogenic DNA sequences (3; 3') derived from a cloning vehicle;

(c) a segment (4) of the wild-type TI plasmid containing DNA sequences essential for the transfer by *Agrobacterium* of the T-region of wild-type TI plasmids into plant cell genomes; and

(d) at least one gene of interest (5) which is under the control of a promoter capable of directing gene expression in plants and which is associated with said border sequence (2) in a manner allowing its integration into the plant genome.

10. The hybrid Ti plasmid vector according to claim 9, containing additionally at least one selectable marker gene, adjacent to the gene(s) of interest (5).

11. The hybrid Ti plasmid vector according to claim 9, wherein the gene(s) of interest (5) is (are) under the control of its (their) natural promoter..

12. The hybrid Ti plasmid vector according to claim 9, wherein the gene(s) of interest (5) is (are) under the control of a promoter which is exogenous with respect to the gene(s) of interest.

13. An Agrobacterium harboring a non-oncogenic Ti plasmid vector system according to

any one of claims 1 to 3.

14. An Agrobacterium harboring a hybrid Ti plasmid vector according to any one of claims 9 to 12.

15. Process for preparing a transformed plant cell comprising the infection of plant cells with an Agrobacterium according to claim 13 or 14.

16. Process for the preparation of a plant comprising the steps of:

(a) infecting a plant cell with an Agrobacterium according to claim 13 or 14; and

(b) generating a plant from the transformed plant cells obtained step (a).

20

25

30

35

40

45

50

55

60

65

19




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig.6






Fig.7




Fig.8




Fig. 9





Fig. 10




Fig. 11




Fig.12





Fig.13






Fig. 15




Fig. 16






Fig.17




Fig.18





Fig.19



**Fig. 20**